Managing Depression During Dementia: Care and Treatment

8 min read

In geropsychology, clinicians recognize that depression can be both a risk factor for dementia and an early symptom of it. Yet depression in the context of cognitive decline is frequently missed. This is not due to lack of care, but because depressive symptoms are often dismissed as “expected” with aging or misattributed to dementia itself, especially in the early stages.

Depression left untreated accelerates problems across multiple domains: physical health worsens, medication burden rises, hospitalizations become more likely, suicide risk increases, family stress deepens, and cognitive decline can progress faster. Treating depression improves mood and quality of life, validates the person’s suffering, and—emerging research suggests—may also slow the progression of dementia.

This article is aimed at clinicians who work with older adults across the full dementia spectrum, from mild cognitive impairment (MCI) through moderate and advanced dementia. It explains why depression is easy to miss, which assessment tools are most appropriate at each stage, and how to adapt effective treatments to cognitive impairment.

Depression in MCI: What the Research Shows

Treating depression in people with MCI, including using SSRIs, appears to do more than relieve mood symptoms; evidence suggests it may delay progression from MCI to dementia. A notable longitudinal analysis found that long-term SSRI use (more than four years) in people with MCI and a history of depression was associated with a roughly three-year delay in progression to Alzheimer’s dementia, after controlling for factors such as age and ApoE4 status. For someone with MCI and depression, three additional years of independence and meaningful engagement can be highly significant.

The MCI stage is a critical intervention window. This is when depression is both most treatable and most consequential for long-term disease trajectory.

Population-based studies also show that baseline depression predicts later development of MCI even after adjusting for socioeconomic, cognitive, and physical health factors. Untreated depression may not only cause suffering but could accelerate cognitive decline.

How Antidepressant Medications May Protect the Brain

SSRIs have been linked to mechanisms that could be neuroprotective, such as stimulating neurogenesis in the hippocampus and shifting amyloid processing toward less toxic pathways. Large retrospective cohort studies using electronic health records have found associations between SSRI exposure (notably citalopram and escitalopram) and reduced risk of progression from MCI to dementia. Clinically, this suggests that treating depression in MCI can be both a quality-of-life intervention and a possible modifier of disease biology.

When Dementia Begins, Depression Often Comes With It

The earliest signs of dementia frequently resemble depression. Before memory loss becomes obvious to family, many people withdraw, lose interest in activities, sleep more, and express hopelessness. Apathy and depression overlap substantially in dementia.

What Is Apathy?

Apathy is a persistent reduction in motivation and initiative, with diminished emotional responsiveness. It is the most common neuropsychiatric symptom in Alzheimer’s disease and may affect a large portion of patients. Apathy also occurs as a symptom of depression, making differential diagnosis important.

What Is Depression?

Depression is also common across dementia stages, with prevalence estimates in the high 30s to low 40s percent range in many studies. Signs of depression in older adults include persistent sadness, crying, feelings of worthlessness, psychomotor slowing, excessive worry about finances or health, appetite or weight changes, restlessness or motor slowing, sleep disturbances, difficulty concentrating, physical complaints such as pain or gastrointestinal problems, and withdrawal from social activities.

To meet criteria for a depressive disorder, an older adult typically needs five or more of these symptoms lasting at least two weeks with associated functional impairment in relationships, self-care, or activity engagement.

Apathy and Depression Often Co-occur

Dementia is a progressive neurodegenerative disease, not a normal part of aging, and neuropsychiatric symptoms—depression, anxiety, apathy, agitation, and psychosis—are part of its clinical picture. These behavioral and psychological symptoms of dementia (BPSD) strongly influence quality of life, caregiver functioning, and the course of care. Research indicates that a large majority of people with early Alzheimer’s disease or MCI will present with at least one clinically significant neuropsychiatric symptom, and a substantial fraction will experience apathy or depression. These symptoms require treatment, not mere accommodation.

The earliest signs of dementia are often apathy and depression—when treated, we can slow disease progression and extend quality of life and independence.

How to Assess for Depression in Dementia

Standard tools like the PHQ-9 were not designed for people with cognitive impairment. Instruments that require sustained attention, multi-step reasoning, or accurate recall of affect over two weeks can give unreliable results as cognition declines. That makes tool selection critical across stages of impairment.

Geriatric Depression Scale–15 (GDS-15)

The GDS-15 is a useful screening tool for older adults with MCI and mild dementia. Its simple yes/no format reduces cognitive load and it omits somatic items that are hard to interpret in those with comorbid medical problems. The GDS-15 shows acceptable sensitivity and specificity in mild-to-moderate dementia, is quick to administer, and can be repeated to monitor response. It is available in many languages.

Cornell Scale for Depression in Dementia (CSDD)

The Cornell Scale was developed specifically for people with cognitive impairment. It combines a structured interview with the patient and a structured informant interview—typically with a family member or caregiver. The CSDD demonstrates high diagnostic accuracy across the cognitive spectrum and generally outperforms self-report measures in populations with dementia. A cutoff score of ≥8 indicates probable depression. The instrument covers mood-related signs, behavioral disturbance, physical signs, cyclical functions (sleep/wake), and ideational disturbance (including suicidal ideation or low self-esteem). Informant input becomes especially valuable when self-report is unreliable.

Neuropsychiatric Inventory (NPI)

For advanced dementia, observational tools administered to caregivers are essential. The Neuropsychiatric Inventory assesses 12 domains—including depression/dysphoria, anxiety, apathy, agitation, and irritability—rating frequency and severity. The NPI and its shorter NPI-Q variant are well suited to track behavioral and mood changes in later-stage dementia when self-report cannot be relied upon. These instruments are widely used in clinical practice and research; commercial use may require licensing in some cases.

Clinical Assessment Principles

Screening scores are only the start. A thorough clinical interview, informant reports, and longitudinal observation provide the most reliable diagnostic picture. Use the GDS-15 in early stages and shift to the CSDD as impairment progresses; administer both when in doubt.

Psychotherapy for Depression in Dementia: Adapting Treatment to Stage

Medication is only one element of care. Psychotherapy, when adapted to cognitive capacity and stage of illness, plays a central role. In early stages, individual therapy can be highly effective. As cognitive impairment progresses, the therapeutic frame often broadens to include caregivers and family systems without excluding the person with dementia.

Individual Psychotherapy in MCI and Early Dementia

People with MCI and early dementia can engage in meaningful therapeutic work: reflecting on experience, identifying patterns, setting goals, and learning coping strategies. Evidence-based approaches include:

Cognitive Behavioral Therapy (CBT): Strong evidence supports CBT for late-life depression, with adaptations for cognitive impairment such as simplified homework, repetition, concrete behavioral activation, and caregiver involvement.
Multicomponent Programs (e.g., CORDIAL): Combining CBT, cognitive rehabilitation, and reminiscence therapy has reduced depressive symptoms in randomized trials of people with MCI or early dementia.
Problem-Solving Therapy (PST): PST is effective for late-life depression and can be adapted for those with executive dysfunction; home-delivered formats with caregiver participation show promise.
Reminiscence/Life Review: Leveraging autobiographical memory supports therapeutic engagement and improves mood and quality of life in early Alzheimer’s disease.

Across these approaches, practical adaptations help: shorter sessions, concrete language, written summaries, and inclusion of a trusted family member as observer or participant.

Caregiver and Family Therapy in Middle and Later Stages

As dementia advances, caregivers’ mental health and coping strategies become primary therapeutic targets because they shape the person’s daily environment and care. Caregivers face elevated rates of depression, anxiety, and burden; treating caregiver distress improves the quality of care and indirectly benefits the person with dementia.

Evidence-based caregiver interventions include structured dyadic or family therapy addressing communication, grief, and role adjustment; multicomponent programs combining psychoeducation, CBT, and caregiver support; CBT adapted for caregivers; and acceptance-based approaches that increase flexibility in responding to stress. Addressing caregiver depression is, in effect, part of treating the person with dementia.

When we treat caregiver stress and mental health and equip them with effective coping strategies, we are also treating the person with dementia.

Treatment Approach by Stage — Summary

MCI / Early-Stage Dementia

Screen with GDS-15; supplement with CSDD when cognitive impairment is significant.
Evaluate for co-occurring mental health conditions.
Discuss SSRI treatment with a medical provider (evidence for citalopram and escitalopram is notable for delay in progression in some studies).
Offer individual psychotherapy (CBT, PST, reminiscence, or multicomponent programs).
Begin caregiver psychoeducation early.

Moderate Dementia

Use the CSDD with an informant interview as the primary screening tool.
Coordinate with medical providers on pharmacotherapy and monitor drug interactions and side effects.
Shift therapeutic focus toward family and dyadic sessions.
Use behavioral activation and environmental modifications to reduce depressive symptoms.
Address caregiver stress and depression as clinical treatment targets.

Advanced Dementia

Rely on observational measures (behavioral indicators, NPI ratings, and informant reports) rather than self-report.
Prioritize comfort, meaningful activity, and environmental calm.
Support caregiver grief, including anticipatory and ambiguous loss.
Treat observed distress with nonpharmacological interventions when possible; continue to address affective and behavioral symptoms.

The Bottom Line

Depression in dementia is common, underdiagnosed, and treatable. Assuming emotional suffering is an inevitable consequence of cognitive decline is a mistake; failing to offer treatment is avoidable and harmful. The evidence indicates that treating depression in MCI—using SSRIs, psychotherapy, or a combination—improves quality of life, benefits caregivers, and may alter the long-term trajectory of cognitive decline. Every person with dementia deserves accurate assessment and appropriate treatment for depressive symptoms at every stage.

Continuing Education

If you want to learn more about providing therapy to people living with dementia and their families, consider accredited continuing education that addresses individual and caregiver-family therapy across dementia stages.

What Is Mild Cognitive Impairment — And How Can Psychotherapy Help?
Supporting People with Dementia Who Live Alone: Must-Have Resources
“What Can I Do to Keep My Brain Healthy?” – Global Council on Brain Health Answers
Suicide Risk After Dementia: Why the First Months Are Most Dangerous
How to Prevent Dementia: 14 New Strategies Revealed
Depression Treatment Prevents Dementia — According to Science
Why Therapy Needs to Change With Age